Table 3 Univariate and multivariate analysis in overall survival.

From: Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Different variables

Univariate analysis

Multivariate analysis

HR (95% CI)

p-value

HR (95% CI)

p-value

Age

< 65/≥ 65

0.44 (0.12–1.21)

0.11

  

Gender

Male/Female

0.52 (0.15–1.45)

0.23

  

Smoking history

Ever/Never

0.55 (0.12–1.68)

0.32

  

ECOG PS

0–1/2

0.07 (0.20–0.28)

< 0.01

0.68 (0.12–5.19)

0.68

EGFR mutation

Ex19 del/L858R

0.68 (0.26–1.83)

0.44

  

Line of previous treatment

2/ ≥ 3

0.39 (0.15–1.03)

0.05

  

Brain metastasis

Yes/No

2.93 (1.14–7.87)

0.02

2.45 (0.48–19.2)

0.29

Detection of major mt (pre)

Yes/No

1.51 (0.54–5.37)

0.45

  

Detection of major mt at 1M

Yes/No

0.77 (0.17–2.45)

0.69

  

Detection of major mt at PD

Yes/No

4.50 (1.11–30.36)

0.03

0.61 (0.03–7.91)

0.71

Detection of T790M (pre)

Yes/No

2.39 (0.90–7.48)

0.07

  

Detection of T790M at 1M

Yes/No

2.72 (0.61–8.79)

0.16

  

Detection of T790M at PD

Yes/No

21.7 (3.81–409.2)

< 0.01

22.4 (2.50–672)

< 0.01

Detection of C797S (pre)

Yes/No

1.34 (0.31–4.09)

0.64

  

Detection of C767S at 1M

Yes/No

2.47 (0.37–9.81)

0.29

  

Detection of C797S at PD

Yes/No

0.88 (0.19–3.07)

0.85

  

Decrease of plasma major mt

Yes/No

0.94 (0.33–3.06)

0.92

  

Decrease of plasma T790M

Yes/No

1.86 (0.65–6.03)

0.24

  
  1. ECOG, eastern cooperative oncology group; PS, performance status; EGFR, epidermal growth factor receptor; major mt, major EGFR mutation (exon 19 deletion or L858R); (pre), at pretreatment; 1M, 1 month after osimertinib administration; PD, progressive disease after osimertinib administration; HR, hazard ratio; 95% CI, 95% confidence interval; Decrease of plasma major mt; decrease of major EGFR mutation in plasma samples from pretreatment to 1 month after osimertinib administration; Decrease of plasma T790M, decrease of T790M in plasma samples from pretreatment to 1 month after osimertinib administration.
  2. Statistically significance values are in bold.
Back to article page